Clinical research sites power every medical breakthrough, but too often, their potential is limited by isolation, outdated tools, and lost opportunities. GLSA Site Nexus was built to change that from the ground up, for sites like yours. Created by site leaders who understand the realities of patient recruitment, site engagement, and study startup, GLSA Site… Read more »
Clinical Research Patient Recruitment Innovation: 2024 Year-End Review By Chris Matheus Clinical research patient recruitment innovation was a central focus for the Global Life Sciences Alliance (GLSA) throughout 2024. As the year comes to a close, we reflect on the progress made across our clinical research services network. These efforts improved trial efficiency, expanded patient… Read more »
Plug-and-Play Clinical Trial Outsourcing: A Smarter CRO Model Plug-and-play clinical trial outsourcing is often described as unrealistic in complex CRO–sponsor relationships. However, at the 11th Annual Outsourcing in Clinical Trials Nordics meeting in Copenhagen, that assumption was directly challenged. Instead, we believe plug-and-play solutions do exist, and Global Life Sciences Alliance (GLSA) proves that every… Read more »
Clinical Research Industry Outlook 2023: GLSA Network Growth The clinical research industry outlook for 2023 revealed a year defined by uncertainty, adaptation, and resilience. As the drug development landscape evolved, Global Life Sciences Alliance (GLSA) remained focused on making meaningful connections that improve clinical trial success and patient outcomes. At the start of the year,… Read more »
COVID-19 Vaccine Development: A Landmark Achievement in Life Sciences Without a doubt, the work accomplished in 2020 by the pharmaceutical, biotech, clinical research, and drug development community—together with the U.S. Food and Drug Administration—deserves special recognition. What the industry achieved was nothing short of extraordinary. Both the FDA and private-sector organizations upheld established good clinical… Read more »
Navigating US Market Access During COVID-19 US life sciences market access has become one of the biggest challenges created by the COVID-19 pandemic. Travel restrictions and lockdowns have limited in-person engagement, forcing companies to rethink how they connect with customers, partners, and decision-makers in the US market. The United States remains the largest life sciences… Read more »